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Abstract
Despite the significant advances in understanding the molecular basis of hearing loss,
precise identification of genetic cause still presents some difficulties, owing to pheno‐
typical variation. Gene discovery efforts for hearing disorders are complicated by ex‐
treme heterogeneity. Mutations in some of these genes, such as GJB2, MYO7A,
CDH23, OTOF, SLC26A4, TMC1, are quite common and responsible for hearing loss.
Clinical exome sequencing is a highly complex molecular test that analyzes the exons
or coding regions of thousands of genes simultaneously, using next-generation se‐
quencing techniques. The development of a biological method for the repair, regener‐
ation, and replacement of hair cells of the damaged cochlea has the potential to
restore normal hearing. At present, gene therapy and stem cells are two promising
therapeutic applications for hearing disorders. Gene therapy and stem cell treatment
have still a long way to go before these treatments will be available to use in humans.
Therefore, existing measures must focus on the prevention of hearing loss to decrease
the frequency of genetic hearing loss. Over time, genetic diagnostic tests will become
available most rapidly, followed by targeted gene therapy or various permutations of
progenitor cell transplantation, and eventually, the preventive interventions for a
wider range of hearing impaired patients.
Keywords: Genetic hearing loss, next generation sequencing, genetic evaluation, gene
therapy, stem cell therapy
1. Introduction
Genetic hearing loss has diverse etiologies and approximately 1% of all human genes are
involved in the hearing process [1]. It is estimated that at least two-thirds of cases of childhood-
onset hearing loss have a genetic cause [2], with the remaining one-third caused by environ‐
mental factors, e.g., cytomegalovirus infection, meningitis, acquired conductive loss, and the
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impact of extracorporeal membrane oxygenation [3]. Many cases of later onset progressive
hearing loss are genetic in origin, and genes also play an important role in progressive hearing
loss associated with ageing. This chapter will deal with the ability to identify genetic problems
or suspected genetic causes in hearing disorders, different types of gene mutation that causes
deafness, genetic evaluation of hearing loss, special aspects of genetic tests such as next-
generation sequencing, limitation of genetic testing, the development and evaluation of genetic
treatment, management, prevention and genetic counseling, benefits of genetic research in
deafness, and research needs/anticipating changes. It will conclude by the direction of possible
future technological development in these aspects.
The majority of hearing loss is caused by mutations in the DNA (deoxyribonucleic acid)
sequence of genes. There are four "bases" in a strand of DNA: adenine (A), guanine (G), thymine
(T), and cytosine (C). The DNA also contains a monosaccharide sugar called deoxyribose and
a phosphate group. According to base pairing rules (A with T, and C with G), hydrogen bonds
bind bases of the two separate strands to make double-stranded DNA. Humans have approx‐
imately 30,000 genes. The DNA sequence of these genes provides the code for producing
proteins (which consist of amino acids). The gene is located within a designated region on the
chromosome and is composed of the different base pairs. The specific location on the chro‐
mosome where the gene is found is known as locus. For example, autosomal recessive deafness
1A (DFNB1A) is caused by mutation in the GJB2 gene on chromosomal locus 13q11-q12. This
means it is on the long arm of chromosome (q indicates the long arm) 13 somewhere in the
range from band 1 of region 1 to band 2 of region 1 (11 or 12 represent the position on arm: 12-
region 1, band 2). At times, changes (INDELs) occur in the DNA sequence of genes, such as a
short segment of a gene is AGACATCATCTA and A has been replaced by a G at position 8
(AGACATCGTCTA) and C at position 4 has been deleted (AGAGATCGTTA), resulting in a
mutation in the DNA sequence and affecting their functions such as a non-functioning protein
may be produced or that protein may be missing altogether. If these mutations occur in a gene
with important information for normal hearing, the result may be hearing loss, or in extreme
cases, deafness.
2. Genetic causes of hearing loss
There are two types of hearing loss caused by genetics. About 30% of people with a genetic
type of hearing loss are classified as syndromic, which involves other presenting abnormalities
along with hearing impairment. Non-syndromic hearing loss occurs when there are no other
problems associated with an individual other than hearing loss. From a genetic standpoint,
this accounts for the other 70% of people, which attributes to the vast majority of genetic
hearing loss.
The genetic basis is highly complex. There are many different ways that the DNA sequence of
a gene can be changed, resulting in different types of mutation. The types of gene mutations
include missence, nonsense, substitution, insertion, deletion, duplication, frameshifts, repeat
expansion, splice site, and translocation. The chances of developing deafness caused by a
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mutated gene depend on whether the mutation is dominant or recessive. Dominant and
recessive hearing loss results from the allelic mutation in some genes, syndromic and non-
syndromic hearing loss is caused by mutations in the same gene, and recessive hearing loss
may be caused by a combination of two mutations in different genes from the same functional
group [4].
2.1. Non-syndromic hearing loss
The different gene loci for non-syndromic deafness are designated DFN (for DeaFNess). Based
on the mode of inheritance, loci are named as A, B, X, and Y for autosomal dominant (DFNA),
autosomal recessive (DFNB), X-linked (DFNX), and Y-linked (DFNY), respectively. The order
in which the loci have been described is denoted by a number after these letters, e.g., DFNB1
is the first identified locus causing autosomal recessive HL [5, 6]. Earlier research reports that
two-thirds of prelingual-onset sensorineural hearing loss (SNHL) is estimated to have a genetic
etiology in developed countries, of which 70% is non-syndromic hearing loss (NSHL).
However, 80% of NSHL is autosomal recessive non-syndromic hearing loss (ARNSHL), 20%
is autosomal dominant (AD), and the remainder is composed of X-linked and mitochondrial
forms [7-9]. NSHL demonstrates extreme genetic heterogeneity, with more than 55 autosomal
dominant (deafness, neurosensory, DFNA), 80 autosomal recessive (deafness, neurosensory,
DFNB), and 5 X-linked (deafness, neurosensory, DFNX) loci with 30, 55, and 4 causative genes,
respectively, identified to date [10]. A fraction of these genes have been associated with both
dominant and recessive HL. Furthermore, mitochondrial mutations can also underlie NSHL.
2.1.1. Autosomal dominant non-syndromic hearing loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) is represented by heterogeneity
of genetic and clinical features. ADNSHL is passed directly through generations. It is often
possible to identify an autosomal dominant pattern through simple inspection of the family
tree. Autosomal dominant traits usually affect males and females equally. ADNSHL associated
with GJB2 mutations is early-onset, moderate to severe, and (in contrast to autosomal recessive
GJB2 related deafness) typically progressive. Dominant GJB2 mutations, however, often have
pleiotropic effects. There is no frequent gene mutated in ADNSHL but WFS1, KCNQ4,
COCH, and GJB2 mutations are somewhat more frequent in comparison to the other reported
genes [2, 11, 12]. Clinical manifestations and loci of known genes causing autosomal dominant
non-syndromic hearing loss are summarized below in Table 1 [13, 14].
Locus Name Gene Onset/Decade Audioprofile
DFNA1 DIAPH1 Postlingual/1st Low frequency progressive
DFNA2 KCNQ4 Postlingual/2nd High frequency progressive
DFNA2B GJB3 Postlingual/4th High frequency progressive
DFNA3 GJB2 Prelingual High frequency progressive
DFNA3 GJB6 Prelingual High frequency progressive
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Locus Name Gene Onset/Decade Audioprofile
DFNA4 MYH14 Postlingual Flat/gently downsloping
DFNA5 DFNA5 Postlingual/1st High frequency progressive
DFNA6/14/38 WFS1 Prelingual Low frequency progressive
DFNA8/12 TECTA Prelingual Mid-frequency loss
DFNA9 COCH Postlingual/2nd High frequency progressive
DFNA10 EYA4 Postlingual/3rd, 4th Flat/gently downsloping
DFNA11 MYO7A Postlingual/1st Flat/gently downsloping
DFNA13 COL11A2 Postlingual/2nd Mid-frequency loss
DFNA15 POU4F3 Postlingual High frequency progressive
DFNA17 MYH9 Postlingual High frequency progressive
DFNA20/26 ACTG1 Postlingual High frequency progressive
DFNA22 MYO6 Postlingual High frequency progressive
DFNA23 SIX1 Prelingual Downsloping
DFNA25 SLC17A8 Postlingual/2nd-6th decades High frequency progressive
DFNA28 GRHL2 Postlingual Flat/gently downsloping
DFNA36 TMC1 Postlingual Flat/gently downsloping
DFNA39 DSPP Postlingual High frequency progressive
DFNA41 P2RX2 Postlingual Flat progressive
DFNA44 CCDC50 Postlingual Low to mild frequencies progressive
DFNA48 MYO1A Postlingual Progressive
DFNA50 MIR96 Postlingual/2nd Flat progressive
DFNA51 TJP2 & FAM189A2 Postlingual/4th High frequency progressive
Table 1. Clinical manifestations and locus of known genes causing ADNSHL. Adapted from [10, 14]
2.1.2. Autosomal recessive non-syndromic hearing loss
Autosomal recessive non-syndromic hearing loss at the DFNB1 locus on chromosome 13q11-12
is characterized as congenital, typically non-progressive, mild to profound hearing impair‐
ment. The locus contains two genes, GJB2 and GJB6. GJB2 and GJB6 are the most common
mutated genes. GJB2 is a small gene with a single coding exon. GJB2 encodes connexin 26, a
gap junction protein of the beta group with a molecular weight of 26 kd. The most common
mutation is a deletion of a single guanine from a string of six (35delG). This mutation accounts
for more than two-thirds of identified mutations and results in a frame-shift with premature
termination of the protein. Profound HL caused by GJB2 gene mutations is found in 50% of
the cases; 30% are severe, 20% moderate and 1-2% are mild cases [15]. GJB2 mutation preva‐
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lence suggests that the overall prevalence of GJB2 mutations is similar around the world,
although specific mutations differ [16].
Mutations  in  the  GJB6  gene  are  the  second  most  common  genetic  defect  in  hereditary
hearing loss and lead to similar effects on abnormal expression of connexin protein Cx30.
However, GJB6 mutations are much less common than mutations in GJB2. In 1999, a research
revealed the  role  for  GJB6,  i.e.,  adjacent  to  GJB2  on  chromosome 13,  when a  dominant
mutation (T5M) was described [17].  The most common mutation in GJB6,  however,  is  a
>300-kb deletion that causes non-syndromic SNHL when homozygous, or when present on
the opposite allele of a GJB2 mutation [18]. GJB6 is very similar to GJB2 and only ∼35 kb
apart, but not interrupted by introns [4, 17]. Both genes are expressed in the cochlea where
they can unite to form multi-unit hemichannels in the cell membrane, and function as an
integral  component of  the potassium regulation in the inner ear.  Clinical  manifestations
and locus of known genes implicated in autosomal recessive nonsyndromic hearing loss
are summarized in Table 2 [10, 14].
Locus Name Gene Onset Type
DFNB1 GJB2 Prelingual 1 Usually stable
DFNB1 GJB6 Prelingual 1 Usually stable
DFNB2 MYO7A Prelingual, postlingual Unspecified
DFNB3 MYO15A Prelingual Severe to profound; stable
DFNB4 SLC26A4 Prelingual, postlingual Stable, progressive
DFNB6 TMIE Prelinqual Severe to profound; stable
DFNB7/11 TMC1 Prelinqual Severe to profound; stable
DFNB8/10 TMPRSS3 Postlingual 2, prelingual Progressive; stable
DFNB9 OTOF Prelingual Usually severe to profound; stable
DFNB12 CDH23 Prelingual Severe to profound; stable
DFNB16 STRC Prelingual Severe to profound; stable
DFNB18 USH1C Prelingual Severe to profound; stable
DFNB21 TECTA Prelingual Severe to profound; stable
DFNB22 OTOA Prelingual Severe to profound; stable
DFNB23 PCDH15 Prelingual Severe to profound; stable
DFNB24 RDX Prelingual Severe to profound; stable
DFNB25 GRXCR1 Prelingual Moderate to profound; progressive
DFNB28 TRIOBP Prelingual Severe to profound; stable
DFNB29 CLDN14 Prelingual Severe to profound; stable
DFNB30 MYO3A Prelingual Severe to profound; stable
DFNB31 CHRN Prelingual —
DFNB32/82 GPSM2 Prelingual Severe to profound; stable
DFNB35 ESRRB Unknown Severe to profound
DFNB36 ESPN Prelingual —
DFNB37 MYO6 Prelingual —
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Locus Name Gene Onset Type
DFNB39 HGF Prelingual Severe to profound; downsloping
DFNB49 MARVELD2 Prelingual Moderate to profound; stable
DFNB53 COL11A2 Prelingual Severe to profound; stable
DFNB59 DFNB59 Prelingual Severe to profound; stable
DFNB61 SLC26A5 Prelingual Severe to profound; stable
DFNB63 LRTOMT Prelingual Severe to profound; stable
DFNB67 LHFPL5 Prelingual Severe to profound; stable
DFNB73 BSND Prelingual Severe to profound; stable
DFNB76 SYNE4 Prelingual High frequency; progressive
DFNB77 LOXHD1 Postlingual Moderate to profound; progressive
DFNB79 TPRN Prelingual Severe to profound; stable
DFNB84 PTPRQ Prelingual Moderate to profound; progressive
Table 2. Clinical manifestations and locus of known genes causing ARNSHL. Adapted from [10, 14].
2.1.3. X-Linked Non-Syndromic Hearing Loss
X-linked non-syndromic hearing loss is much rarer, accounting for 1-3% of hereditary deafness
[19]. So far, there are only four genes that have been associated with X-linked non-syndromic
hearing loss. These are: PRPS1 on Xq22 that encodes phosphoribosyl pyrophosphate (PRPP)
synthetase 1; POU3F4 on Xq21, encoding a member of a transcription factor family that
contains a POU domain; SMPX on Xp22 that encodes the small muscle protein; and COL4A6
on Xq22 encoding the alpha-6 chain of type IV collagen. COL4A6 is a protein-coding gene, type
IV collagen having an important role in cochlea development. The COL4A6 gene is located
only ~500 kb away from the DFNX1/PRPS1 locus [20]. Clinical manifestations and locus of
known genes causing X-linked nonsyndromic hearing impairment are summarized in Table
3 [10, 14].
Locus Name Gene Onset Type and Degree Frequencies
DFNX1 (DFN2) PRPS1 Postlingual Progressive sensorineural; severe to profound All
DFNX2 (DFN3) POU3F4 Prelingual Progressive, mixed; variable, but progresses to
profound
All
DFNX4 (DFN6) SMPX Postlingual Progressive sensorineural; mild to profound All
DFNX6 COL4A6 Postlingual Progressive Sensorinueral, mixed; mild to
severe
All
Table 3. Clinical manifestations and locus of known genes causing X-linked non-syndromic hearing loss. Modified
from [10, 14].
2.1.4. Non-syndromic mitochondrial hearing loss
Mitochondrial DNA (mtDNA) mutations account for at least 5% of cases of postlingual, non-
syndromic hearing impairment [21]. MtDNA mutations are classified as either large-scale
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rearrangements (partial deletions or duplications) that are usually sporadic or point mutations,
which are usually maternally inherited, and concern genes responsible for protein synthesis
(rRNAs or tRNAs), or genes encoding subunits of the electron transport chain (ETC) [22, 23].
Tang et al. reported that mitochondrial mutations by themselves are not sufficient to produce
a deafness phenotype. Modifier factors such as nuclear and mitochondrial genes, or environ‐
mental factors such as exposure to aminoglycosides, appear to modulate the phenotypic
manifestations [24].
The mutation most commonly associated with maternal inheritance is A1555G on gene 12S
rRNA, MTRNR1 [25, 26]. Non-syndromic mitochondrial hearing loss is characterized by
moderate-to-profound hearing loss and a pathogenic variant in either MTRNR1 or MTTS1.
Pathogenic variants in MTRNR1 can be associated with the predisposition to aminoglycoside
ototoxicity and/or late-onset sensorineural hearing loss. [27].
The use of streptomycin, and to a lesser extent other aminoglycoside antibiotics, can cause
hearing loss in genetically susceptible individuals. These drugs are known to exert their
antibacterial effects at the level of the decoding site of the small ribosomal subunit, causing
miscoding or premature termination of protein synthesis [28-30]. The hearing loss is primarily
high frequency and may be unilateral. Mitochondrial non-syndromic sensory neural hearing
loss (SNHL) is also associated with the A7445G, 7472insC, T7510C, and T7511C mutations in
the tRNASer (UCN) gene,MTTS1 [30, 31]. Mitochondrially inherited non-syndromic hearing
loss can be caused by mutation in any one of several mitochondrial genes, including MTRNR1,
MTTS1, MTCO1, MTTH, MTND1, and MTTI (Table 4).










7472insC Neurological dysfunction, including ataxia, dysarthria, and
myoclonus
7510T->C No additional symptoms
7511T->C No additional symptoms
MTCO1 7444G>A Aminoglycoside associated; associated with
MTRNR1 1555A >G
MTTH 12201T-C No additional symptoms
MTND1 3388C-A Tinnitus and BPPV associated
MTTI 4295A-G Hypertrophic cardiomyopathy
Table 4. Identified mitochondrial DNA mutations in hearing loss. Modified from [10].
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2.2. Syndromic hearing loss
Syndromic forms of hearing loss are less common than non-syndromic forms. To date, more
than 400 genes responsible for syndromic hearing loss have been identified [32]. These can
include syndromes transmitted in Mendelian or monogenic, syndromes due to chromosomal
anomalies, syndromes due to multi-factorial influences, or syndromes due to a combination
of these. Syndromic hearing loss can be conductive, sensorineural, or mixed.
Many of the syndromes associated with SNHL do not usually demonstrate gross inner ear
anomalies. However, inner ear malformations are common in numerous syndromes. In some
cases, the existence of specific inner ear anomalies may be characteristic of certain syndromes
such as in BOR syndrome, Waardenburg syndrome, or X-linked deafness with stapes gusher
or CHARGE syndrome. SNHL presenting later in life is often related to inner ear infections or
inflammatory conditions, trauma, or tumor [33].
Mutations in the same gene may cause syndromic hearing loss in one individual and non-
syndromic hearing loss in another. The most common autosomal dominant form is Waarden‐
burg syndrome. The most common autosomal recessive forms are Pendred syndrome and
Usher syndrome. Syndromic hearing loss may be transmitted as an autosomal recessive,
autosomal dominant, X-linked, or matrilineal trait. Some of the genetics forms of syndromic
hearing loss and their main clinical features are given in Table 5 [34].
Syndrome Main Clinical Features Genetics Hearing loss
Waardenburg
syndrome (AD)*
⋅ Type 1: dystopia canthorum, iris
heterochromy, brilliant blue eyes, broad nasal
root, premature, graying of hair, white forelock,
and vestibular dysfunction
PAX3 Sensorineuralhearing loss
⋅ Type 2: similar phenotype except dystopia
canthorum MITF, SNAI2
⋅ Type 3 (Klein-Waardenburg syndrome ):
upper extremity abnormalities other Type 1
clinical features
PAX3
⋅ Type 4 (Waardenburg-Shah syndrome):
pigmentation abnormalities and
Hirschsprung’s disease other Type 2 clinical
features
EDN3, SOX10 and EDNRB
Charge ⋅ Choanal atresia Mutations in Severe-to-
syndrome ⋅ Coloboma CHD7 are profound
(AD) ⋅ Characteristic ears detected in asymmetrical
⋅ Cranial nerve anomalie more than 75% mixed losses
⋅ Cardiovascular malformations of CHARGE
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Syndrome Main Clinical Features Genetics Hearing loss
⋅ Genital hypoplasia patients




Pierre Robin ⋅ Micrognathia Genetic Typically
Sequence ⋅ Glossoptosis heterogeneity conductive and
(AD) ⋅ Cleft palate bilateral
Stickler ⋅ Long and flat face Mutations in Both
syndrome ⋅ Malar and mandibular hypoplasia COL2A1, sensorineural and
(AD) ⋅ Small nose with a depressed nasal bridge COL9A1, COL9A2, conductive
and anteverted nares COL11A1, and
⋅ Altered vision COL11A2 genes
⋅ Joint problems
Branchio-oto-renal
(BOR) syndrome ⋅ Branchial cleft, cysts, or fistulae EYA1, SIX1, and SIX5 Sensorineural,
(AD) ⋅ Ear abnormalities mutations conductive, or
⋅ Kidney abnormalities mixed hearing loss
Treacher- Collins ⋅ Zygomatic arches hypoplasia Genetic About 40-50% of
syndrome ⋅ Hypoplasia of supraorbital rims heterogeneity: patients with
(AD) ⋅ Micrognathia TCS-1, TCS-2 Treacher Collins
⋅ Narrow face and TCS- 3 have conductive
⋅ Antimongoloid slant of the eyes and have been hearing loss. Few
hypertelorism related to cases of mixed
⋅ Coloboma of the lower lid with mutations in hearing loss have
deficiency of cilia medial to the coloboma TCOF-1, POLR1D been described.
⋅ Large nose is with hypoplastic alae and POLR1C
⋅ Down-turning mouth respectively
⋅ Cleft palate
⋅ External ear abnormalities
Apert syndrome ⋅ Craniosynostosis FGFR2 mutations Mild to moderate
(AD) ⋅ Frontal bossing conductive
⋅ Wide set eyes hearing loss
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Syndrome Main Clinical Features Genetics Hearing loss
⋅ Hypoplastic midface
⋅ Proptosis
⋅ Small upper jaw
⋅ Syndactyly
Crouzon ⋅ Synostosis FGFR2 Conductive





⋅ Hypoplastic upper jaw
Saethre- Chotzen ⋅ Brachycephaly TWIST1 Conductive or mixed
syndrome ⋅ Low frontal hair line
(AD) ⋅ Flattened nasofrontal angle




⋅ Broad or duplicated thumb or hallux
Pfeiffer syndrome ⋅ Broad face is midface hypoplasia FGFR1 & Conductive
(AD) ⋅ Prognatism FGFR2
⋅ High forehead, flat occiput, hypertelorism
⋅ Swallowing orbits which cause proptosis
⋅ Skull malformation
⋅ Limb abnormalities
Townes-Brock ⋅ Anus imperforatus It is caused by Sensorineural or
syndrome ⋅ Rectovaginal mutations in conductive
(AD) ⋅ Rectoperineal fistula SALL1 hearing loss
⋅ External ear anomalies
⋅ Thumbs malformation
Miller syndrome ⋅ Malar hypoplasia DHODH Conductive
(AR** or AD) ⋅ Micrognathia hearing loss-
⋅ Down-slanting eyes mainly due to
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Syndrome Main Clinical Features Genetics Hearing loss
⋅ Coloboma anomalies of
⋅ Cleft palate middle ear
⋅ Limb defects
Nager syndrome ⋅ Limbs abnormalities Not known Conductive or
(Sporadic, AD or ⋅ Maxillar hypoplasia mixed hearing
AR) ⋅ Micrognatia Loss
Goldenhar ⋅ Hemifacial microsomia Genetic Ranges from
syndrome ⋅ Auricular malformations heterogeneity mild to moderate
(Sporadic, AR or ⋅ Vertebrae abnormalities conductive
AD) ⋅ Facial cleft impairment and
⋅ Ocular abnormalities severe to profound
⋅ Congenital heart diseases sensorineuralhearing loss
Usher Syndrome ⋅ Type 1: vestibular dysfunction onset MYO7A, USH1C, CDH23, Profound hearing
(AR) of retinitis pigmentosa in childhood PCDH15,USH1G & CIB2, Loss
⋅ Type 2: normal vestibular response VLGR1, WHRN, PDZD7 Mild to moderate
retinitis pigmentosa begins in the second
decade of life hearing loss
⋅ Type 3: variable vestibular response, USH3A, CLRN1 Progressive hearingloss
variable onset of retinitis pigmentosa
Pendred syndrome ⋅ Abnormal iodine metabolism (goiter) SLC26A4 , FOXI1, KCNJ10 Usually bilateral,severe to
(AR) profound
Jervell & Lange-
Nielsen ⋅ SIDS, syncopal episodes prolongation of KCNQ1, KCNE1
Sensorineural
hearing loss
(AR) the QT interval
Perrault syndrome ⋅ Ovarian dysfunction in females, HSD17B4, HARS2, LARS2 Sensorineuralhearing loss
(AR) ⋅ Intellectual disability,
⋅ Loss of sensation and weakness in the limbs
Alport syndrome
(AR,AD, X-Linked)
⋅ Renal abnormalities including
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Syndrome Main Clinical Features Genetics Hearing loss












⋅ Developmental delays in motor skills
⋅ Mild to moderate intellectual disability
NDP SensorineuralProgressive HL
*AD- Autosomal dominant inheritance, **AR- Autosomal recessive inheritance
Table 5. Syndromic hearing loss and their clinical features. Modified from [34].
3. Genetic evaluation of hearing loss
Despite the significant advances in understanding the molecular basis of hearing loss, precise
identification of genetic cause still presents some difficulties due to phenotypical variation.
Gene discovery efforts for hearing disorders are complicated by the extreme heterogeneity.
Usher syndrome or Jervell and Lange-Nielsen syndrome, which can be mistaken for nonsyn‐
dromic hearing loss, where Usher syndrome can be caused by mutations in several different
genes. We must therefore have a clear understanding of the different types of diagnostic tests
available to patients, including karyotyping, RFLP, FISH, microarray, clinical exome sequenc‐
ing, preimplantation genetic diagnosis, and newborn genetic screening. Establishing a genetic
diagnosis of hearing loss is a critical component of the clinical evaluation of hearing impaired
persons and their families. If a genetic cause of hearing loss is determined, it is possible to
provide families with prognostic information, recurrence risks, and improved habilitation
options [9].
The identification of genes or genetic cause for hearing loss is a breakthrough approach. First
we have to rule out non-genetic causes, then syndromic causes, and then look for non-
syndromic causes. Mutations in some of these genes, such as GJB2, MYO7A, CDH23, OTOF,
SLC26A4, TMC1 are quite common for responsible of hearing loss. GJB2 mutations are the most
frequent cause of autosomal recessive non-syndromic hearing loss (ARNSHL) and account for
about 20% of the cases, therefore routine screening begins with GJB2 analysis [35]. Newborns
that are diagnosed with severe-to-profound HL (in the absence of other abnormal findings on
physical examination) are analyzed for mutations in the GJB2 gene. For abnormalities such as
an enlarged vestibular aqueduct indicated by imaging of the inner ear, the SLC26A4 gene is
analyzed. It is exceptional to find any gene other than GJB2 and SLC26A4 that is routinely
analyzed in DNA diagnostics. In such cases, a positive result is only obtained in less than 20%
of deaf children for which DNA diagnostics is requested [2, 36]. The key challenge lies in
determining which gene is responsible in a patient with hearing loss. Sequencing all genes by
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traditional DNA sequencing technology is labor-intensive and not cost-effective [35, 36]. In
such case, next-generation sequencing offers rapid sequencing of the entire human genome
compared to traditional molecular testing that focuses on a single gene at a time. However,
Sanger sequencing is still recommended for first-line diagnostics. It is currently the standard
for molecular diagnosis of unknown point mutations in known genes. Screening can be cost-
effective in individuals with genetically heterogeneous hearing loss phenotypes when a single
gene is responsible for a significant percentage of cases.
3.1. Next-generation sequencing
With the fast development and wide applications of next-generation sequencing (NGS)
technologies, genomic sequence information is within reach to aid the achievement of goals
to decode life mysteries and improve life qualities. Today, NGS-based tests are rapidly
replacing traditional tests, which include many single gene-sequencing tests for hearing loss.
These tests use disease-targeted exon capture, whole-exome sequencing (WES), or whole-
genome sequencing (WGS) strategies. The main advantage of these tests is that they address
the problem of genetic heterogeneity, where many different genes result in phenotypes that
cannot be easily distinguished clinically [36-39]. NGS also offers sequencing of very large gene
or in presence of substantial locus heterogeneity, where it may be difficult to analyze the same
gene by comprehensive Sanger sequencing.
NGS systems are typically represented by SOLiD/Ion Torrent PGM from Life Technologies,
Genome Analyzer/HiSeq/MiSeq/NextSeq from Illumina, and GS FLX Titanium/GS Junior from
Roche. Today, Illumina dominates the genome sequencing market, where instrument versa‐
tility, high throughput and accuracy, turnaround speed, faster and simpler sample prepara‐
tion, and supportive data analysis software make it a driving force and the clear winner as of
now. Their technology creates new applications and also decipher many existing genetic
research and clinical diagnostic markets.
Targeted genomic capture and massively parallel sequencing technologies are revolutionizing
genomics by making it possible to sequence complete genomes of model organisms. However,
the cost and capacity required are still high, especially considering that the functional signif‐
icance of intronic and intergenic noncoding DNA sequences is still largely unknown. One
application that these technologies are well suited for is the re-sequencing of many selected
parts of a genome, such as all exons, from a large set of genes. This requires that the targeted
parts of the genome are highly enriched in the sample. Recent technological changes, such as
genome capture, genome enrichment, and genome partitioning, have successfully been used
to enrich large parts of the genome [40-42]. The targeted fragments can subsequently be
captured using solid- or liquid-phase hybridization assays [43, 44].
Clinical exome sequencing or whole-exome sequencing is a highly complex molecular test that
analyzes the exons or coding regions of thousands of genes simultaneously from a small
sample of blood, using NGS techniques. Exome sequencing is especially valuable when a
patient’s symptoms suggest numerous possible genetic causes. The whole-exome sequencing
test sequences base by base with the required depth of coverage to achieve accurate consensus
sequence rather than limiting the testing to a single gene or panel of genes and incurring
Advances in Genetic Diagnosis and Treatment of Hearing Loss — A Thirst for Revolution
http://dx.doi.org/10.5772/61218
65
diagnostic delays and escalating costs. It is possible to identify point mutations, insertions,
deletions, inversions, and rearrange the exome.
Hearing status Locus/disorder Gene Strategy References
Nonsyndromic
Recessive
DFNB79 TPRN Targeted enrichment of
genomic locus
[48]
DFNB82 GPSM2 Whole exome [49]
DFNB84 OTOGL Whole exome [50]
Dominant DFNA4 CEACAM16 Whole exome [51]
DFNA41 P2RX2 Targeted enrichment of
genomic locus
[52]
X-Linked DFNX4 SMPX Targeted enrichment of
genomic locus
[53]
Syndromic Perrault syndrome HSD17B4 Whole exome [54]







MASP1 Whole exome [56]
Hereditary sensory and
autonomic neuropathy
type 1 (HSAN1) with
dementia and hearing loss
DNMT1 Whole exome [57]
Table 6. Deafness genes identified using genomic capture and massively parallel sequencing.
Among NGS applications, whole-exome sequencing is a cost-effective alternative to whole-
genome sequencing. The total size of the human exome is ~30 Mb, which comprises ~180,000
exons that are arranged in about 22,000 genes and constitute about 2-3% of the entire human
genome, but contains ~85% of known disease-causing variants. The exome refers to the portion
of the human genome that contains functionally important sequences of DNA that direct the
body to make proteins essential for the body to function properly. Research revealed that most
of the errors that occur in DNA sequences are usually located in the exons that lead to genetic
disorders. Consequently, sequencing human exome is considered to be an efficient method to
discover the genetic cause of hearing disorders. Currently, sequencing whole genomes is still
a substantial undertaking, which is not a routine procedure that can be done on hundreds of
samples. At present, exome sequencing represents an alternative in which, approximately
30-70 Mb sequences encompassing exons and splice sites are targeted, enriched, and sequenced
using commercially available sequence capture methods. Several Human Exome Sequence
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Capture kits are now commercially available. These include the Agilent SureSelect Human All
Exon Kit, the Illumina Nextera Rapid Capture Exome and Nextera Rapid Capture Expanded
Exome Kit, the TargetSeq In-solution Target Enrichment Kit from Life Tech/Applied Biosys‐
tems, and SeqCap EZ Exome from Roche NimbleGen. Clinical exome sequencing should be
considered in the diagnostic assessment of a phenotype individual when a genetic disorder is
suspected clinically, but limited genetic testing is available clinically, the patient’s features are
unclear or atypical, there are multiple genetic conditions as part of the differential diagnosis,
and a novel or candidate gene is suspected but has yet to be discovered.
Hundreds of syndromic forms of deafness have been described, and for many of them, the
underlying genes still await discovery. Since the introduction of the first NGS technology in
2004, more than 1,000 NGS-related manuscripts have been published. Until now, approxi‐
mately a dozen of genes for HL have been successfully determined using NGS [45-47] (Table 6).
3.1.1. Sequencing panels
Consider a case where there is an interest in a large but limited subset of particular genes, not
the whole genome, or even the whole exome, but more than just one or two genes. This sort
of situation frequently arises in the context of oncology, where the characterization of a set of
oncogenes on a set of pathways can help stratify cases and select the best therapeutic options.
These may consist of 30-150 particular target genes, with a desire to have high throughput by
analyzing multiple different specimens within a single NGS run. Generally referred to as “NGS
panels,” this is a third form of library which, depending on design, may start with extracting
genomic DNA from a test sample where selection of targets of interest is performed. This can
be by gene-specific PCR, leading to a pool of amplicons (already of the desired length, although
in this case with defined endpoints), by hybridization capture, or by selective genomic DNA
coding only for particular genes. This genetic material is then a very focused subset of the
source genome from which to prepare the library material for dispersion and sequencing,
following either of the paths above as appropriate to the sample type (note that for a direct
PCR amplified genomic DNA panel type, the size shearing and adapter ligation steps may be
dispensed with as these are effectively carried out in the PCR step).
A particularly clever aspect of NGS panels is that it is possible, either in the direct PCR stage
for genomic DNA-based panels or in the adapter ligation step for exome-based panels, to use
PCR primers or adapters, respectively, which contain an internal sequence element (commonly
referred to as a “barcode”) that is distinct to each sample prepared. This then allows multiple
panel libraries from different samples to be mixed together prior to the dispersion and actual
sequencing steps. By doing this, each individual sequence read will start with a sample-unique
“barcode,” allowing it to be associated back to the sample of origin. This allows many different
unrelated panel sample libraries to be mixed together in one dispersion and sequencing run,
thereby taking full advantage of the massively parallel nature of NGS technology and allowing
for high throughput with respect to the number of samples per run. This makes panels highly
cost-effective and of relatively low labor input on a per-sample basis. Depending on the type
of research or clinical question being addressed in an NGS assay, the choice of the best method
helps to make results cost-effective and most directly meaningful.
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Different panels designed to diagnose hearing loss include:
• Hearing Loss Panel Tier 1—testing for mutations in GJB2, GJB6, MTRNR1, and MTTS1 that
account for 40% of the genetic causes of hearing loss. Reflex testing to OtoSeq® Hearing
Loss Panel is an option for patients with normal Tier 1 results. This panel contains 23 genes,
which identifies an estimated 80% of the genetic causes of hearing loss.
• OtoGenomeTM Test Panel offered by Partners Healthcare. This test panel simultaneously
screens 87 genes known to cause both non-syndromic hearing loss and syndromes that can
present as isolated hearing loss, such as Usher, Pendred, Jervell and Lange-Nielsen (JLNS),
Branchio-Oto-Renal (BOR), Deafness and Male Infertility (DIS), Perrault, and Waardenburg
syndromes.
3.1.2. NGS data analysis
The large amount of data derived from NGS platforms imposes increasing demands on
statistical methods and bioinformatic tools for the analysis. Although the NGS platforms rely
on different principles and differ in how the array is made, their work flows are conceptually
very similar. All of them generate millions or billions of short sequencing reads simultane‐
ously. Several layers of analysis are necessary to convert these raw sequence data into
understanding of functional biology. These include alignment of sequence reads to a reference,
base-calling and/or polymorphism detection, de novo assembly from paired or unpaired reads,
and structural variant detection (Figure 1). To date, a variety of software tools are available for
analyzing NGS data. Although tremendous progress has been achieved over the last several
years in the development of computational methods for the analysis of high-throughput
sequencing data, there are still many algorithmic and informatics challenges remaining. For
example, even if a plethora of alignment tools have been adapted or developed for the
reconstruction of full human genotypes from short reads, this task remains an extremely
challenging problem. Also, when a high-throughput technology is used to sequence an
individual (the donor), any genetic difference between the sequenced genomes and a reference
human genome—typically the genome maintained at NCBI—is called the variant. Although
this reference genome was built as a mosaic of several individuals, it is haploid, and may not
contain a number of genomic segments present in other individuals. By simply mapping reads
to the reference genome, it is impossible to identify these segments. Thus, de novo assembly
procedures should be used instead. Nonetheless, NGS technologies continue to change the
landscape of human genetics. The resulting information has both enhanced our knowledge
and expanded the impact of the genome on biomedical research, medical diagnostics, and
treatment, and has accelerated the pace of gene discovery [47].
Clinical diagnostic using NGS technologies may be applicable in such cases where clinicians
consider a non-syndromic hearing disorder, especially after negative results on tests for
mutations in the autosomal recessive DFNB1 locus for GJB2 or GJB6, according to recently
published guidelines [39, 58]. Updated guidelines from the American College of Medical
Genetics and Genomics (ACMG) recommend that clinicians consider NGS when testing for
genetic causes of hearing loss [56]. Prior to considering genetic testing, clinicians should
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undertake a comprehensive evaluation of the patients' medical histories, including birth, that
will help distinguish acquired versus inherited causes of hearing loss. They should also
perform audiological evaluations to determine the type and degree of hearing loss, as recom‐
mended by ACMG. ACMG also recommends genetic testing and counseling that could include
 
Figure 1. Next-generation sequencing: An approach from sample to analysis.
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single-gene tests, panels, genome/exome sequencing, chromosome analysis, and array-based
copy number analysis if clinical findings suggest syndromic genetic hearing loss. Single-gene
testing may be needed if medical and family history suggests non-syndromic hearing loss that
is not associated with environmental causes. If none is suggested, the next step could be GJB2
or GJB6 testing. If single-gene tests yield no diagnosis, clinicians may consider NGS that
quickly replaces many single-gene tests for hearing loss and can assess patients whose
phenotypes are not easily distinguished clinically [58].
3.2. Cytogenetics
Cytogenetic tests are a diagnostic tool for a number of clinical syndromes associated with
hearing loss. They proved the causal association between specific chromosomal abnormalities
and clinical features observed in patients. Although cytogenetics is not the first technique to
be considered when evaluating a child with non-syndromic deafness, this form of testing could
be valuable in cases of deafness of unknown etiology, particularly if there were accompanying
congenital anomalies, or a family history of multiple spontaneous abortions. When all other
causes of deafness are eliminated, cytogenetics could be used to determine if the hearing loss
may be due to a chromosome rearrangement, such as a balanced translocation. The advantage
would be that, if such a chromosome rearrangement were found, it would immediately suggest
the location of the deafness gene [59].
Cytogenetic or molecular cytogenetic tests such as karyotyping, fluorescent in situ hybridiza‐
tion (FISH), or chromosomal microarray analysis (CMA) may provide diagnostic information
when syndromes characterized by chromosomal aneuploidies, structural rearrangements, or
deletions or duplications are suspected. Genetic testing of specific individual genes (PAX3 for
Waardenburg syndromes types I and III), or small panels of genes related to a specific clinical
finding (FGFR-related craniosynostosis panel) may be appropriate, depending on the sus‐
pected diagnosis [60].
3.2.1. Prenatal diagnosis
Prenatal diagnosis of chromosomal aberrations requires cytogenetic analysis of amniotic fetal
cells. Amniocentesis is an invasive, well-established, safe, and reliable test during pregnancy
that removes a small amount of fluid from the sac around the baby to look for birth defects
and chromosomal problems. Amniocentesis is done from 12 to 15 weeks of gestation for
chromosomal analysis. When the amniotic sample is received in the laboratory, it is centrifuged
at 750 rpm for 10 minutes. The amniotic fluid is then carefully decanted from the cell pellet
into a sterile test tube, and then the cell pellet is re-suspended in amniotic fluid. Then, suitable
medium supplemented with fetal bovine serum, L-glutamine, and antibiotics are added and
the cultures are incubated at 37ºC in 5% CO2 incubator. The cells are harvested at 8-10 days
after culture, subjected to routine hypotonic and fixative treatments as for whole blood culture,
and then the chromosomes are analyzed [61].
Genetic screening for a specific mitochondrial mutation during pregnancy could offer a
strategy of minimizing hearing loss in babies from exposure to avoidable risk factors such as
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neonatal use of aminoglycoside antibiotics [3]. Genetic counseling should ideally be offered to
all pregnant women who have a family history of any condition that might be tested by either
amniocentesis or chorionic villus sampling (CVS). It is important to offer genetic counseling
before and after prenatal diagnostic testing. The important aspects should be considered such
as presentation of the background risk of congenital disease and anomaly, and individual
increased risks (such as increased maternal age), options and limitations for prenatal genetic
diagnosis, possible diseases that can be detected, risks associated with the relevant tests, and
conflictual areas in relation to prenatal diagnosis and alternatives. [62]. Different techniques
used in genetic analysis and their applications are summarized in Table 7.
Techniques Applications Year, Discovered/
Reported by
References
Sanger Sequencing Sequencing of targeted genes to analyze
variations
1975, Frederick Sanger [63]
FISH (fluorescence in situ
hybridization)
Detect and localize the presence or absence






Variations in homologous DNA sequences 1984, Sir Alec Jeffreys [65]
Microarray Copy number variation of numbers of genes
involved in disease
1995, Schena et al. [66]
qRT-PCR Copy number variations of targeted genes 1996, Heid et al. [67]
SMRT (Single molecule
real time sequencing)
Detects variations of entire genome and/or
coding regions, genome resequencing,
transcriptome profiling, DNA-protein





Clinical exome sequencing Analyzes the exons or coding regions of
thousands of genes simultaneously
2009, Sarah B Ng et al. [69]
Table 7. Different techniques used in genetic analysis and applications.
Molecular genetic testing can be helpful because an etiology cannot be otherwise established
in the majority of individuals with genetic hearing loss. Molecular analysis is essentially non-
invasive and may reduce the need for more extensive and expensive testing; it sometimes
requires sedation or general anesthesia of infants and children. Molecular analysis can be
beneficial for the diagnosis of syndromic hearing loss before additional features emerge (e.g.,
in Pendred syndrome or Jervell and Lange-Nielsen syndrome), and can distinguish individ‐
uals with mitochondrial mutations who are at risk for iatrogenic hearing loss when treated
with aminoglycosides [4]. There are other benefits of molecular analysis, which include
associated knowledge of the pattern of inheritance and more accurate genetic counseling.
Recently developed high-throughput techniques reduce the burden of the costs of sequencing.
Advances in Genetic Diagnosis and Treatment of Hearing Loss — A Thirst for Revolution
http://dx.doi.org/10.5772/61218
71
For example, sequencing costs have massively reduced from $5,292.39/Mb in 2001 to $0.06/Mb
by April 2013 [70]. It is estimated that the sequencing costs will further reduce with precipitous
dropping per-base cost with advancing techniques.
3.3. Limitations and challenges
Despite the significant advantages of genetic testing, there are also several limitations and
challenges. These limitations and challenges are briefly discussed below:
• The spectrum of DNA variation in a human genome comprises small base changes (substi‐
tutions), insertions and deletions of DNA, large genomic deletions of exons or whole genes,
and rearrangements such as inversions and translocations. Traditional Sanger sequencing
is restricted to the discovery of substitutions and small insertions and deletions [71].
• Although NGS promises a personalized approach to complex diseases, it has limitations.
NGS cannot detect large deletions or duplications of DNA or nucleotide repeats that can
cause disease. These limitations of NGS technologies may necessitate use of alternative or
complementary genetic testing strategies in some cases.
• Not all regions of the genome are efficiently captured and analyzed by current exon-capture
or WGS approaches, and large deletions and duplications, in addition to copy-number and
structural variations, may not be efficiently detected [72].
• It is possible to determine with recent technology if an asymptomatic newborn has a
mutation in the genes known to be implicated to hearing loss, although there is no certainty
that all of these genes will be responsible for the incidence of hearing loss in the future.
• Current methods of DNA analysis require 2-5 mls of blood, which would be unacceptable
for a newborn screen. However, It is anticipated that sufficient DNA could be extracted from
a drop of blood collected for newborn bloodspot metabolic screen, with improved sequence
techniques (the Guthrie test) [3].
• Genetic testing for deafness is not collectively perceived to be advantageous. Deafness is
not usually considered to be negative or limiting especially by the deaf community. Many
deaf individuals consider themselves to be part of their own linguistic (sign language) and
cultural group, where they have their own values, identity, and traditions. It is not perceived
to be a medical condition or disability. As a result, advances in hearing loss research and
genetic testing might be perceived as harmful. Genetic services may be considered; however,
some individuals prefer to have deaf children [4, 73].
• A positive genetic test can also lead to an increased level of anxiety and individuals may
feel guilty for having potentially passed a gene alteration on to their children.
4. Development and evaluation of genetic treatment for hearing loss
Despite recent developments in medicine, there is still no cure for most types of hearing loss.
The development of a biological method for the repair, regeneration, and replacement of hair
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cells of the damaged cochlea has the potential to restore normal hearing. At present, gene
therapy and stem cells are two promising therapeutic applications for hearing disorders.
4.1. Gene therapy
Gene therapy involves using specific sequences of DNA to treat human disease. It is an
experimental form of treatment that is still being developed, but it has a unique application
for hearing loss. Two main gene therapy approaches have been considered: replacing a
mutated gene that causes disorder with a healthy copy of the gene, or inactivating a mutated
gene that is functioning improperly. Gene therapy technology has improved in recent years,
making it a promising technique for treating hearing disorders. The gene vector, the route of
gene administration, the therapeutic gene, and the target cells are four major elements of gene
therapy. With the recent developments in the field, a wide variety of viral and non-viral vectors
have emerged that can deliver genetic payloads to target cells in the inner ear. There are three
viral vectors commonly utilized for gene therapy (targeted at the inner ear): adenoviral vectors,
adeno-associated viral vectors, and lentiviral vectors. Several promising clinical trials have
been reported using gene therapy.
The first study of gene therapy for hearing disorders was reported in 1994 by Fujiyoshi and
colleagues. They developed the myelin basic protein (MBP) transgenic mice by microinjecting
an MBP cosmid clone into the pronucleus of fertilized eggs of shiverer mice to replace the
autosomal recessive mutation (deletion) gene by the transgene for MBP. The MBP transgenic
mice were found to recover up to 25% of normal levels of MBP, and significantly higher
myelinated axons were present in the transgenic mice compare to control mice [74, 75]. In 1996,
other studies reported that foreign genes were successfully transfected into the inner ear using
replication-deficient viral vectors [75-77].
The discovery of RNA interference (RNAi)-mediated gene inactivation has introduced a new
mechanism for targeted therapy of the inner ear at the molecular level [78]. RNAi is an
intracellular two-step process that converts precursor double-stranded RNA molecules into
functional small interfering RNAs (siRNAs). Synthetic double-stranded RNAs can be intro‐
duced as siRNA mimics and used to trigger RNAi and intentionally reduce the expression of
targeted genes for therapeutic applications. A few allele variants of GJB2 cause autosomal
dominant non-syndromic hearing loss as a dominant-negative consequence of expression of
the mutant protein. Allele-specific gene suppression by RNAi is a potentially attractive
strategy to prevent hearing loss caused by this mechanism [79]. Since inheritance is autosomal
dominant, silencing the mutated allele is predicted to preserve hearing. A recent proof-of-
principle study validated this prediction—an siRNA was shown to potently suppress expres‐
sion of the R75W allele of human GJB2 in a murine model [79, 80].
Bacterial artificial chromosome (BAC) mediated transgenesis has proven to be a highly reliable
way to obtain accurate transgene expression for in vivo studies of gene expression and
function. BAC transgenes direct gene expression at physiological levels with the same
developmental timing and expression patterns as endogenous genes in transgenic animal
models. Recently, transgene expression through the germline was demonstrated to maintain
normal inner ear morphology and stable hearing function in a mouse model of human non-
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syndromic deafness DFNB3 caused by a missense mutation in the Myo15a gene on mouse
chromosome 11. In addition, excess Myo15a expression has no physiologically significant
protective or deleterious effects on hearing of normal mice, suggesting that the dosage of
Myo15a may not be problematic for gene therapy [80, 81].
Neurotrophic factors are essential in the development of the inner ear and are able to protect
inner ear hair cells and spiral ganglion neurons from the damage caused by various pathogenic
factors and promote the recovery from cochlear injury. Up to now, more than 20 neurotrophic
factors have been revealed with protective effects on inner ear cells [75]. Neurotrophin gene
therapy is promising both in the protection against exogenous damage and the regeneration
after endogenous and exogenous damage. It has been reported that neurotrophic factors, such
as BDNF (brain-derived neurotrophic factor), NT-3 (neurotrophins 3), TGF (transforming
growth factor), GDNF (glial cell line-derived neurotrophic factor), FGF (fibroblast growth
factor), CNTF (ciliary neurotrophic factor), and HGF (hepatocyte growth factor) have protec‐
tive effects of different extents on inner ear hair cells and neurons [82-86].
The discovery of new therapies for the treatment of hereditary hearing loss will depend on a
better understanding of gene function in the survival and differentiation of existing neurons,
and encourages the growth and differentiation of new neurons and synapses, bonding nerves
to cochlear hair cells to form synaptic connections as well as in maintaining the unique inner
ear ion balance.
Atoh1 (Math1) gene acts as a “switch” to turn on hair cell growth and it is discovered that Atoh1
is artificially switched on in the cells that support hair cells (called “supporting cells”); it
instructs them to divide and form new hair cells. Atoh1 (Math1) plays an important role in the
differentiation of hair cells of the developing inner ear and restore auditory function [87-89].
Using the tools of gene therapy may activate Atoh1 to induce undamaged cells within the
cochlea to develop into hair cells in an adult human ear and rebuild a damaged ear by
replicating the steps that took place during embryonic development. There is still a lot of work
to be done for human adult ear. CGF-166 gene therapy has been shown to activate the Atoh1
biological pathway and the gene was able to safely restore hearing in animal models. Recently,
the clinical trial started to test if CGF166 will have the same beneficial effect in humans [90].
Researchers believe that this therapy would not help people with types of inherited deafness
where the structures in the ear needed to support new hair cell growth are missing or those
who have damaged auditory nerves.
There is no ideal gene delivery system for gene therapy so far. Three kinds of vectors (bacterial
vector, multiplex gene vector, labeled gene vector) may have great prospects. Long-term
human gene therapy will not be feasible until there is substantial improvement in transduction
efficiencies into human tissues. The combination of more efficient gene transfers, targeted
vector systems, and effective and relatively nontoxic selection systems to maintain gene
expression may make the long-term correction of hearing disorders feasible and safe. Some
practices of inner ear gene therapy may need to be carried out at the embryonic stage for the
treatment of hereditary hearing loss in the future.
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4.2. Stem cells therapy
The recent developments in stem cell technologies are opening novel therapeutic possibilities
for the treatment of hearing disorders. Stem cell therapy is a relatively new technique used to
treat many forms of human disease in which exogenous stem cells are used to replace dead or
damaged endogenous cell types. In recent years, researchers have undertaken a number of
successful animal studies in the area of developing stem cell therapies for hearing loss and
able to turn stem cells into many of the cell types in the inner ear whose damage and death
leads to hearing loss, such as hair cells and auditory nerve cells.
Stem cells are a group of cells in our bodies with the capacity to self-renew and differentiate
to various types of cells, thus to construct tissues and organs. When a stem cell divides, each
new cell has the potential either to remain undifferentiated (self-renewal) or become a
specialized (differentiation) type of cell with a specific function. Stem cells can be classified
into different types, based on their source of origin, the time of derivation, and the potential
to produce different lineages. The primordial master stem cell is the zygote. The zygote and
early blastomeres are totipotent and can generate any and all human cells type in the body,
such as the brain, liver, blood, or heart cells. It can even give rise to a whole functional organism
including extraembryonic tissues. Pluripotent stem cells have a slightly more limited potential.
They have the ability to produce cell types from all three embryonic germ layers (endoderm,
mesoderm, and ectoderm), including all the somatic lineages as well as germ cells; but
infrequently, if ever, can produce extraembroynic lineages such as those from the placenta. It
cannot form an entire functional organism. Lastly, multipotent stem cells such as hemato‐
poietic stem cells have a more limited ability, producing cell types usually restricted to a single
organ or germ layer. Multipotent stem cells have the ability to differentiate into a closely related
family of cells. Pluripotent stem cells have the widest range of potential applications. They can
generally be classified as embryonic or adult, depending on their developmental stage of
derivation.
Embryonic and adult stem cells differ primarily in the number of different cells each can
produce. Embryonic stem cells are derived from a four- or five-day-old embryo that is in the
blastocyst phase of development. It can develop into any cell type of the body. In contrast,
adult stem cells reside in many organs of the adult human body and can generate a range of
cell types from the originating organ or even regenerate the entire original organ. Adult stem
cells can be found in a great number of organs and tissues including the brain, bone marrow,
peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian epithe‐
lium, and testis [91]. A relatively recent breakthrough in stem cell research is the discovery
that specialized adult (somatic) cells can be ‘reprogrammed’ into cells that behave like
embryonic stem cells, termed induced pluripotent stem cells (iPSCs) [92]. Like human
embryonic stem cells, the iPS (induced pluripotent stem cells) cells are immortal, pluripotent,
and express genes characteristic of all three embryonic germ cell layers (endoderm, ectoderm,
and mesoderm) when induced to differentiate.
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A number of criteria must be satisfied to achieve functional restoration, including generation
of an adequate number of cells to invert the defects, differentiation of the cells to the correct
phenotype, formation of appropriate three-dimensional tissue structures, and production of
cells/tissues that are mechanically and structurally complaint with the native tissue without
immunological rejection [80, 93]. The generation of neural stem cells and control of neural
differentiation from human embryonic stem cells have opened new doors for therapy of
hearing disorders. Several studies have demonstrated successful delivery of embryonic and
adult stem cells to normal and damaged tissues in vivo, and in some cases a therapeutic effect
has been observed.
One of the first reports of stem cell delivery to the inner ear was a study by Ito and colleagues
(2001) that demonstrated survival and migration of adult rat hippocampus-derived neural
stem cells (NSCs) implanted into the rat cochlea. Within 2-4 weeks of grafting to the cochlea,
some NSCs survived in the cochlear cavity. Some of them had adopted the morphologies and
positions of hair cells [94]. Following this study was a report about the potential of NSC
transplantation to the damaged mouse cochlea. The majority of transplanted cells integrated
in the vestibular sensory epithelia and expressed specific markers (myosin VIIa) for hair cells
in vivo. The result of this study suggests that transplanted NSCs have the potential to differ‐
entiate and restore inner ear hair cells. However, a small number of hair cell marker-positive
grafted cells and no evidence of synaptic connections between transplants and host spiral
ganglion neurons hampered well-established methods for functional recovery [95]. The
principal differences between human and mouse NSCs seem to be the length of the cell cycle
(up to 4 days in humans) and the predilection of human cells to senesce (after ~100 cell
divisions) [96]. NSCs can achieve therapeutic efficacy in human clinical applications, although
many limitations remain to be overcome.
Several studies reported on the transplantation of embryonic stem (ES) cells into the inner ear.
ES cells have the ability to differentiate into neuronal cell types when transplanted into the
spiral ganglion of cochlea. ES cells that have been transplanted into the spiral ganglion of the
cochlea were found to express neural markers [97, 98] and develop cellular processes similar
to axons that extend towards the organ of Corti [99-102]. Some of these stem cell-derived
neurons were shown to establish synaptic contacts with sensory hair cells, the peripheral target
for spiral ganglion neurons (SGNs) in vitro (Matsumoto et al., 2008) and to survive in animals
with selective loss of SGNs [99, 103].
For a cell therapy approach aiming at restoring impaired function, implanted cells need to be
able to convey auditory information from the periphery to more centrally located nuclei.
Recent studies have shown that dorsal root ganglion cells or ES cells are transplanted to the
transected auditory nerve migrated along the nerve fibers in the internal auditory meatus and,
in some cases, even reach proximate to the ventral cochlear nucleus in the brainstem [104,
105]. Interestingly, Ito et al. (2001) reported that embryonic brain tissue transplanted to the
acutely transected ventral cochlear tract resulted in not only regeneration but additionally
functional recovery [105, 106]. However, there are many chemical factors that produce a barrier
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between the peripheral and central nervous system and could impede the ability of central
processes of replacement neurons to make a connection in the cochlear nucleus.
A number of studies have shown that adult bone marrow-derived stem cells (MSCs) can also
have therapeutic potential in the damaged inner ear. MSCs have shown plasticity with a
capacity to differentiate into a variety of specialized cells. MSCs have been delivered both
systemically and by direct injection through the scala tympani into the mouse and gerbil
cochlea respectively [107, 108]. Matsuoka and colleagues investigated the potential of MSCs
to adopt properties of SGNs in vivo [108]. Identification of stem cells in the human fetal cochlea
[109] contributes to the study stem cell biology of the auditory organ in humans, while
advances in identification of stem cells have been made in rodents [110].
Umbilical cord blood (UCB) is the most recently identified useful source of hematopoietic stem
cells (HSCs) for treatment of a wide variety of disorders. UCB has potential applications in
hearing disorders. A study provided the first evidence of positive engraftment of intrave‐
nously transplanted human umbilical cord blood CD133+ HSCs into the inner ear of NOD-
SCID mice rendered deaf with kanamycin and noise in vivo [111]. In another study, the
researchers have demonstrated that hematopoietic stem cell transplantation (HSCT) may
provide improvement in mucopolysaccharidosis-associated sensorineural hearing loss [112].
Recently, an FDA-approved clinical trial involving stem cells derived from UCB has been
initiated for treatment of children with sensorineural hearing loss [113].
Mammalian cochlear hair cells do not regenerate spontaneously, although vestibular hair cells
in adult mammals regenerate at levels so low as to rule out any significant functional recovery
[114, 115]. The discovery of stem cells has opened the possibility of devising strategies to recruit
these cells to repair damaged or lost cochlear hair cells. Stem cells are important tools for
hearing disorder research and offer great potential for use in the clinic. Certain types of stem
cells, such as neural stem cells, are more capable than others of replacing lost or damaged hair
cells, although they have limitations. There is a great challenge in identifying more effective
ways of directing stem cells to develop into inner ear hair cells. The field of auditory stem cell
research is still in its infancy, although important advances are already taking place. Stem cell
therapy for hearing loss is some years away from being clinically feasible.
5. Management and prevention of hereditary hearing loss
Gene therapy and stem cell treatment have still a long way to go before these treatments will
be available to use in humans. Therefore, existing measures must focus on the prevention of
hearing loss to decrease the frequency of genetic hearing loss. There is a need of improved
implementation of genetic counseling and awareness in populations that are at high risk of
hereditary hearing loss.
Early detection and intervention of hearing loss is the most important factor in minimizing the
impact of hearing loss on a child’s development and educational achievements. At least, all
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children with a risk for hereditary hearing loss need to be given screening audiometry. The
hearing loss can be progressive in nature for a person with autosomal recessive non-syndromic
hearing loss caused by mutations in SLC26A4. In such case, audiometric testing may be
warranted every year. Additionally, thyroid function should be followed if the diagnosis is
consistent with Pendred syndrome [14]. Sequential audiologic examinations are essential to
document the stability or progression of the hearing loss and to identify and treat superim‐
posed hearing losses, such as middle ear effusion.
Knowledge of the genetic cause is helpful in determining the kind of damage to the auditory
system that caused deafness. Identification of the underlying cause in terms of how the inner
ear is damaged may assist in choosing rehabilitation strategies, such as hearing aid or cochlear
implant. In children with congenital severe-to-profound autosomal recessive non-syndromic
hearing loss who are positive for mutations in GJB2 and GJB6 at the DFNB1 locus and who
elect to receive cochlear implants, performance outcome is outstanding [116]. In addition, a
recent cochlear implant study stated that children with identified GJB2 mutations, which cause
an isolated insult to the cochlea without damage to the 8th nerve or the central auditory system,
benefitted from cochlear implantation in the areas of speech production, speech perception,
and language [4].
5.1. Genetic counseling
Genetic counseling is an important part of evaluation and management of hearing disorders.
The process of genetic counseling is intended to inform patients and their families of the
medical, psychological, and familial implications of genetic hearing disorders, as well as the
risks, benefits, and limitations of genetic testing. In the United States, genetics professionals
recommend "non-directive" counseling. It is meant to be informative and supportive rather
than advise people what to do or whether or not to have children. Genetic information can
help predict whether the hearing loss will remain the same or whether it will worsen over time.
In addition, genetic testing can help determine if problems besides hearing loss may be present
or may develop in the future. It can also help patients and families who may be at risk for
conditions that can be passed down in families (inherited conditions). There are a number of
people who may have quite different attitudes about deafness in their family. Some hearing
parents might be concerned about having another deaf child, while others may believe that
the hearing loss would not cause a problem, but they would want to know if any other
associated medical problems might be involved. Likewise, deaf parents may feel comfortable
about their own abilities, but would have a better opinion of not to have a deaf child, in view
of the fact that other deaf parents may be more worried about the challenges of raising a hearing
child [117]. In such case, the genetic counselor should be very cautious in providing informa‐
tion concerning the nature of the disease, the implications of being carriers (mutation carriers
of genes associated with hearing loss), and the reproductive choices. Genetic counseling
services for families with deafness can only be effective and appropriate if the social values of
the deaf community are taken into consideration.
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6. Conclusions and future perspectives
Advances in genetic testing are already directly impacting people’s lives. The demand for
molecular tests is by now increasing with the discovery of the varied molecular defects
underlying hearing loss. Genetic testing has now reached a stage where it is becoming
increasingly applicable for precise diagnosis of hearing disorders. The development of NGS
technology has made DNA sequencing not only rapid and cost-effective, but also highly
accurate and reproducible. In the near future, it is expected that there will be more enhance‐
ments in the speed and cost of DNA sequencing. We are already in the modern DNA se‐
quencing era, where aims of third- and fourth-generation DNA sequencing additionally boost
the speed of sequencing and reduce costs. Although sequencing the whole genome seems
exhaustive, it could be more cost-effective than having to select the genes of interest [118]. Once
genome sequencing becomes more cost-effective and fast, it will accelerate the pace of gene
discovery for deafness and clinical application of this discovery will be realized. Over the next
few years, most molecular genetic testing will be performed on automated instruments and
some genetic tests for hearing disorders will be available as at-home kits on a large scale.
One of the roles of genetic testing is to identify presently known genetic causes of hearing loss
in failed hearing screening of newborns and children who are identified with childhood-onset
hearing loss. Furthermore, it increases our knowledge of the genetic causes of hearing loss.
The potential for increased usage of aminoglycoside antibiotics also supports the case for a
genetic screening program of pregnant women for the m.1555A G mutation, which could avoid
unnecessary cases of hearing loss. Only when a reliable estimate of the future risks of hearing
loss can be made at a reasonable cost will genetic screening become viable [3].
Molecular diagnostic results should always be interpreted with caution, as our knowledge of
the molecular basis of hearing loss is still evolving. Keeping pace with emerging clinical genetic
technologies requires specialized genetic training as well as broad genetic literacy for patients
and clinicians ordering and receiving genetics test results. Genetic information that is shared
by the patient and patient's family is unique. The application of genetic tests has appropriately
generated substantial debate in the community with regard to the delivery and impact of the
information on clinicians, patients, and society in general. The potential for misuse of genetic
information is enormous and requires action to protect the privacy of genetic information and
protect individuals from discrimination based on genetic information. The ethical, legal, and
social issues surrounding genetic testing for hearing loss need to be addressed. In the near
future, more studies of the ethical and social aspects of genetic testing for hearing disorders
should be done. It is hoped that the potential for misuse of genetic information in the future
will be limited.
Some of the novel rehabilitation options under development to slow down the progression of
hearing loss are gene and even mutation specific [80], suggesting that comprehensive genetic
testing will be an integral part of the care of deaf and hard-of-hearing patients in the future [9].
Over time, the genetic diagnostic tests will become available faster, followed by targeted gene
therapy or various permutations of progenitor cell transplantation, and eventually, the
preventive interventions for a wider range of hearing impaired patients.
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